BTIG Maintains Buy on Tvardi Therapeutics, Lowers Price Target to $5
Tvardi Therapeutics Inc TVRD
$2.10
▲ +0.00%
(+$0.00)
🎈 Low Float
🗓️ Earnings Next Week
Open
$2.08
Prev Close
$2.10
Day Range
$2.00 – $2.13
52W Range
$1.50 – $43.65
Market Cap
$19.70M
Beta
0.35
EPS (TTM)
$-1.60
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2014-01-31 |
| Shares Out. | 12,490,000 |
| Website | tvarditherapeutics.com ↗ |
| Phone | 17134898654 |
| Employees | 12 |
| Net Income | -$6.8M |
| Total Assets | $25.8M |
| Total Liabilities | $11.3M |
| Equity | $14.5M |
About Tvardi Therapeutics Inc
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
Tvardi Therapeutics Inc is a publicly traded company under the ticker symbol TVRD on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
15 analysts (2026-07-01)